OMX Ventures
Venture capitalLincolnshire · Seed–Series A · 9 people tracked
Investment thesis
OMX Ventures takes a technology-first, first-principles approach, prioritizing groundbreaking solutions over established executive rosters. Leveraging a deep network of advisors, the firm seeks disruptive opportunities that others overlook and supports founders with focused research and valuable networks. It emphasizes deep technical and intellectual property expertise, working hands-on with founders to hit milestones, establish strong IP, and attract follow-on capital. The firm's supportive ecosystem is geared toward helping biological solutions grow into scalable companies.
Source: firm website, verified Aug 11, 2026.
Team · 9 people
from the firm's website & public directories
What they invest in
from 17 of 35 portfolio companiesBiotech ×16Deep Tech ×9Medical Devices ×6AI & Machine Learning ×5Digital Health ×4Healthtech ×4AgTech ×1FemTech ×1
HQs:United States×10
Investments · 35 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 12019 · 12018 · 14 dated
Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology.
AgTechBiotechDeep TechRoboticsBoston, US
Jason Kelly(Co-founder & CEO)Reshma Shetty(Co-founder, President & Chief Operations Officer)Barry Canton(Foundry Technology Strategy & Direction)Austin Che(Strategic Partnerships & Investments)Tom Knight(Founder, Ginkgo Fellow)
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Rob Chess(Director)
BoardKeith Crandell(Director)Paul Conley(Director)
Aperiam Bio uses computational methods to identify stabilizing mutations in proteins, producing variants with improved expression, solubility, and activity for applications in technical reagents, cosmetics, and pulmonary therapeutics.
AI & Machine LearningBiotechDeep TechAustin, US
Austin Cole(Executive Officer, Director)
Developing patent-protected psilocybin formulations for treating intractable mood disorders.
Constructive develops synthetic biology technology using recoded genomes and engineered tRNAs to incorporate novel chemical building blocks into proteins, enabling new therapeutics, materials, and manufacturing applications.
BiotechDeep TechNew Materials
Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.
AI & Machine LearningBiotechDigital Health
Developing microbiome-based drugs for conditions including recurrent C. difficile, ASD, Hepatitis B, and IBD.
Finch is a microbiome therapeutics company that develops innovative microbiome assets designed from human microbiota transplantation studies, targeting a range of therapeutic areas.
BiotechMedical DevicesSomerville, US
R. J. Price(Director)Jeffery A. Smisek(Director)Mark Smith(Executive Officer, Director)Andrew Mulderry(Director)Chris Lange(Director)James Burgess(Director)
Freya Biosciences is a clinical-stage immunology company developing therapies targeting inflammation and immune dysregulation in conditions affecting women, including infertility and pregnancy-related dysbiosis.
BiotechFemTechHealthtech
Institutional co-founder for science-based companies, providing expertise, operations, and capital.
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Joshua Yang(Founder & CEO)Daniel Estandian(Founder)Ed Boyden(Founder)Jimmy Yun(Director)
BoardCraig Asher(Director)
BiotechBoulder, US
Michael Graige(Executive Officer)John R. Stuelpnagel(Director)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)Bryan Roberts(Director)
Machine-learning software platform enabling faster mass spectrometry analysis of metabolomics samples.
Developing a chemoproteomics platform to identify and target novel hotspots across the proteome.
Creating a toolkit to deliver large DNA payloads to any cell type for the cell and gene therapy market.
Engineering yeast metabolism to use cheap feedstocks to produce high-value chemicals and enzymes.
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)Aashish Manglik(Co-founder)Jeff Landau(Chief Executive Officer)Roland Gendron(Chief Business Officer)Michelle Zhang(Chief Scientific Officer)
BoardVineeta Agarwala(Director)
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Paul Smith(Executive Officer, Director)Geoff Smith(Founder & CEO)Jason Betley(Chief Product Officer)
Yeast engineering approach to discover peptide-based drugs blocking tough-to-drug protein-protein interactions.
Predictive cardiac tissue models for cardiac toxicology, precision cardiology, and heart failure drug discovery.
Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.
Digital HealthHealthtechMedical DevicesSeattle, US
Ben Casavant(Co-Founder and Chief Executive Officer)Erwin Berthier(Co-Founder and Chief Technology Officer)Alan Levy(Director)
BoardElizabeth Hambrecht(Director)Paul Conley(Director)
Developing bifunctional kinase inhibitors to drug historically hard-to-target cancers.
VedaBio develops a molecular detection platform using CRISPR technology that enables rapid, accurate detection of multiple biological targets without the need for amplification.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Diego, US
Anurup Ganguli(Founder)inFred(President and CEO)Frédéric Sweeney(President and Chief Executive Officer)Maurice Exner(Chief Operating Officer)
Exits · 3
IPOs and acquisitions across the tracked portfolioCompass PathwaysNASDAQ: CMPSGinkgo BioworksNYSE: DNATwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companiesGinkgo Bioworks · ca.investing.com · Jul 17, 2026
Twist Bioscience · biospace.com · Jul 16, 2026
Lightcast · kb.lightcast.io · Jul 2, 2026
Tessera · erp.today · Jun 26, 2026
Frequently asked questions
- What stage does OMX Ventures invest at?
- OMX Ventures invests at the Seed, Series A stages.
- What sectors does OMX Ventures focus on?
- OMX Ventures focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is OMX Ventures located?
- OMX Ventures is headquartered in Lincolnshire, US.
- Does OMX Ventures lead rounds?
- OMX Ventures typically participates in rounds rather than leading them.
Co-investors · 1
Northpond Ventures is a science- and technology-driven investment firm that backs breakthrough businesses aiming to have a significant impact on humanity.
Firms observed investing alongside OMX Ventures, from public investor directories. Shared companies are the overlap with OMX Ventures's recorded portfolio.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
Draper Associates is a venture capital firm that invests in technology startups across AI, robotics, blockchain, healthcare, aerospace, and frontier deep-tech fields.
Seventure Partners is a European venture capital firm investing across life sciences, digital technologies, sport and performance, and the blue economy.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.